Evidence map›Paper›PMID 40396746›Full record

ArticlemSphere2025

Sudapyridine (WX-081) inhibits

Xinda Li, Xiaoyi Luo, Bin Wang, Lei Fu, Xi Chen, Yu Lu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinda Li *Department of Pharmacology, Beijing Chest Hospital, Capital Medical University, Beijing, China.ORCID 0009-0006-8278-9413
Xiaoyi Luo *Department of Pharmacology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Bin WangDepartment of Pharmacology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Lei FuDepartment of Pharmacology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Xi ChenDepartment of Pharmacology, Beijing Chest Hospital, Capital Medical University, Beijing, China.
Yu LuDepartment of Pharmacology, Beijing Chest Hospital, Capital Medical University, Beijing, China.ORCID 0000-0002-9038-1884

Funding

Beijing Municipal Administration of Hospitals DFL20221402National Natural Science Foundation of China 82304570
6 · The paper itself

Abstract

Drug-resistant tuberculosis (DR-TB) urgently requires safer, more accessible alternatives to bedaquiline (BDQ), which faces critical flaws like cardiotoxicity, high costs, and emerging resistance. WX-081, a promising BDQ alternative, has demonstrated superior anti-TB activity and improved safety in clinical studies. However, its mechanism of action remains unexplored, underscoring the need for further research to optimize its potential in advancing global TB elimination efforts. This study reveals WX-081's dual mechanisms: targeting

Indexed as

Antitubercular AgentsImmunity, InnateMycobacterium tuberculosisAnimalsDiarylquinolinesHumansMacrophagesMiceMolecular Docking SimulationPyridinesTuberculosis, Multidrug-ResistantUp-RegulationAntitubercular AgentsDiarylquinolinesPyridinessudapyridineATP synthasedrug-resistant tuberculosisimmunomodulationWX-081

Identifiers

PMID40396746
PMCPMC12188713

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.